165 related articles for article (PubMed ID: 30828862)
1. Topical sirolimus as an effective treatment for a deep neurofibroma in a patient with neurofibromatosis type I.
Malhotra N; Levy JMS; Fiorillo L
Pediatr Dermatol; 2019 May; 36(3):360-361. PubMed ID: 30828862
[TBL] [Abstract][Full Text] [Related]
2. Pilot study for the treatment of cutaneous neurofibromas in neurofibromatosis type 1 patients using topical sirolimus gel.
Wataya-Kaneda M; Watanabe Y; Nakamura A; Yamamoto K; Okada K; Maeda S; Nimura K; Saga K; Katayama I
J Am Acad Dermatol; 2023 Apr; 88(4):877-880. PubMed ID: 36334988
[No Abstract] [Full Text] [Related]
3. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.
Weiss B; Widemann BC; Wolters P; Dombi E; Vinks A; Cantor A; Perentesis J; Schorry E; Ullrich N; Gutmann DH; Tonsgard J; Viskochil D; Korf B; Packer RJ; Fisher MJ
Neuro Oncol; 2015 Apr; 17(4):596-603. PubMed ID: 25314964
[TBL] [Abstract][Full Text] [Related]
4. Occult neurofibroma and increased S100 protein in the skin of patients with neurofibromatosis type 1: new insight to the etiopathomechanism of neurofibromas.
Karvonen SL; Kallioinen M; Ylä-Outinen H; Pöyhönen M; Oikarinen A; Peltonen J
Arch Dermatol; 2000 Oct; 136(10):1207-9. PubMed ID: 11030766
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and clinicopathological characteristics of lipomatous neurofibromas in neurofibromatosis 1: An investigation of 229 cutaneous neurofibromas and a systematic review of the literature.
Rozza-de-Menezes RE; Brum CAI; Gaglionone NC; de Sousa Almeida LM; Andrade-Losso RM; Paiva BVB; Faveret PLS; da Silva AV; Siqueira OHK; Riccardi VM; Cunha KS
J Cutan Pathol; 2018 Oct; 45(10):743-753. PubMed ID: 29959804
[TBL] [Abstract][Full Text] [Related]
6. Comparative Effects of Topical 0.2% Sirolimus for Angiofibromas in Adults and Pediatric Patients with Tuberous Sclerosis Complex.
Lee YI; Lee JH; Kim DY; Chung KY; Shin JU
Dermatology; 2018; 234(1-2):13-22. PubMed ID: 29925060
[TBL] [Abstract][Full Text] [Related]
7. Pseudoatrophic macules associated with neurofibromatosis-1.
Chiu CS; Wang JD; Yen CY; Chen YJ; Shen JL
Pediatr Dermatol; 2009; 26(2):231-2. PubMed ID: 19419486
[TBL] [Abstract][Full Text] [Related]
8. Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.
Cannon A; Sarin KY; Petersen AK; Pichard DC; Wolters PL; Erickson G; Lessing AJ; Li P; Röhl C; Rosser T; Widemann BC; Blakeley JO; Plotkin SR
Clin Trials; 2024 Feb; 21(1):67-72. PubMed ID: 37269078
[TBL] [Abstract][Full Text] [Related]
9. Sirolimus improves pain in NF1 patients with severe plexiform neurofibromas.
Hua C; Zehou O; Ducassou S; Minard-Colin V; Hamel-Teillac D; Wolkenstein P; Valeyrie-Allanore L
Pediatrics; 2014 Jun; 133(6):e1792-7. PubMed ID: 24864177
[TBL] [Abstract][Full Text] [Related]
10. Does Schwann cell dedifferentiation originate dermal neurofibromas?
Iribar H; Jaka A; Ormaechea N; Tuneu A; Izeta A; Gutiérrez-Rivera A
Exp Dermatol; 2016 Nov; 25(11):901-903. PubMed ID: 27303947
[TBL] [Abstract][Full Text] [Related]
11. Considerations for development of therapies for cutaneous neurofibroma.
Verma SK; Riccardi VM; Plotkin SR; Weinberg H; Anderson RR; Blakeley JO; Jarnagin K; Lee J
Neurology; 2018 Jul; 91(2 Suppl 1):S21-S30. PubMed ID: 29987132
[TBL] [Abstract][Full Text] [Related]
12. Bilateral cranio-orbital neurofibromas in a 16-year-old child with neurofibromatosis 1.
Li P; Yang Z; Wang Z; Liu P
Neurol India; 2016; 64(4):835-6. PubMed ID: 27381153
[No Abstract] [Full Text] [Related]
13. Cutaneous angiomyolipoma masquerading as a neurofibroma in a child with neurofibromatosis type 1: a case report.
Carrau D; Kahwash S; Pearson G
Pediatr Dermatol; 2015; 32(3):423-4. PubMed ID: 25640861
[TBL] [Abstract][Full Text] [Related]
14. Neurofibroma of the breast in a boy with neurofibromatosis type 1.
Murat A; Kansiz F; Kabakus N; Kazez A; Ozercan R
Clin Imaging; 2004; 28(6):415-7. PubMed ID: 15531141
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous neurofibromas in Neurofibromatosis type I: a quantitative natural history study.
Cannon A; Chen MJ; Li P; Boyd KP; Theos A; Redden DT; Korf B
Orphanet J Rare Dis; 2018 Feb; 13(1):31. PubMed ID: 29415745
[TBL] [Abstract][Full Text] [Related]
16. Cervical segment nervus vagus neurofibroma with associated neurofibromatosis type 1: a case report.
Guler AK; Gunaldi O; Alis H; Tugcu B; Tanriverdi O; Colluoglu B
Minim Invasive Neurosurg; 2009 Oct; 52(5-6):246-9. PubMed ID: 20077367
[TBL] [Abstract][Full Text] [Related]
17. Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1.
Sarin KY; Bradshaw M; O'Mara C; Shahryari J; Kincaid J; Kempers S; Tu JH; Dhawan S; DuBois J; Wilson D; Horwath P; de Souza MP; Powala C; Kochendoerfer GG; Plotkin SR; Webster GF; Le LQ
Sci Adv; 2024 May; 10(18):eadk4946. PubMed ID: 38691597
[TBL] [Abstract][Full Text] [Related]
18. Topical delivery of mitogen-activated protein kinase inhibitor binimetinib prevents the development of cutaneous neurofibromas in neurofibromatosis type 1 mutant mice.
Coulpier F; Pulh P; Oubrou L; Naudet J; Fertitta L; Gregoire JM; Bocquet A; Schmitt AM; Wolkenstein P; Radomska KJ; Topilko P
Transl Res; 2023 Nov; 261():16-27. PubMed ID: 37331503
[TBL] [Abstract][Full Text] [Related]
19. Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study.
Weiss B; Widemann BC; Wolters P; Dombi E; Vinks AA; Cantor A; Korf B; Perentesis J; Gutmann DH; Schorry E; Packer R; Fisher MJ
Pediatr Blood Cancer; 2014 Jun; 61(6):982-6. PubMed ID: 24851266
[TBL] [Abstract][Full Text] [Related]
20. Melanocytic nevi are associated with neurofibromas in neurofibromatosis, type I, but not sporadic neurofibromas: a study of 226 cases.
Ball NJ; Kho GT
J Cutan Pathol; 2005 Sep; 32(8):523-32. PubMed ID: 16115049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
